🚀💰 The AI revolution continues unabated! Causaly, a cutting-edge startup in the preclinical discovery realm, secures a fresh $60 million investment, with support from former Johnson & Johnson chair and CEO, Alex Gorsky.
💼 London and San Francisco-based Causaly, in their Series B announcement on Thursday, proudly revealed their association with 12 out of the top 20 pharma giants, including Gilead, Novo Nordisk, Regeneron, and the FDA.
🔬 Causaly’s advanced systems play a vital role in target identification, biomarker research, disease pathophysiology, and other impactful projects. By meticulously analyzing millions of publications, they empower discovery scientists to unravel disease mechanisms and discover innovative treatment avenues.
🔍 Committed to expediting drug discovery and development, Causaly focuses on tackling “unsolved diseases of our age,” such as Parkinson’s, lung cancer, and multiple sclerosis.
⚙️ While many techbio and AI companies venture into clinical programs, Causaly primarily concentrates on serving its customers, prioritizing their preclinical programs’ success rates.
🌐 CEO and co-founder Yiannis Kiachopoulos emphasizes the importance of knowledge in research organizations, stating that Causaly’s mission is to make scientific data discoverable, helping customers gain valuable insights and make evidence-driven decisions.
💡 Alex Gorsky, renowned for championing AI’s potential, is among the notable supporters of Causaly’s Series B funding round. ICONIQ Growth leads the way, with additional backing from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures, Visionaries Club, and Datadog CEO Olivier Pomel.
💭 Gorsky envisions a future where treatments spanning therapeutics, robotics, and artificial intelligence converge to revolutionize disease prevention, interception, and cure. He serves on the boards of Apple and IBM, both dedicated to advancing AI and transformative healthcare initiatives.
🌍 AI Startup Stay tuned as Causaly and its allies drive the frontiers of AI-powered innovation in healthcare and shape a promising future of improved patient outcomes.
AI Startup
